| Trial ID: | L0044 |
| Source ID: | NCT04237116
|
| Associated Drug: |
Secukinumab
|
| Title: |
A Study of Secukinumab Treatment in Patients With Plaque Psoriasis and Coexisting Non-alcoholic Fatty Liver Disease (NAFLD)
|
| Acronym: |
pINPOINt
|
| Status: |
Completed
|
| Study Results: |
No Results Available
|
| Results: |
--
|
| Conditions: |
Plaque Psoriasis|Non-alcoholic Fatty Liver Disease
|
| Interventions: |
Biological: Investigational Arm - secukinumab|Biological: Control Arm - placebo
|
| Outcome Measures: |
Percentage of participants achieving ??? 90% improvement (reduction) in PASI score compared to Baseline|Serum Alanine Aminotransferase (ALT) level|Percentage of patients achieving DLQI 0/1 at week 12
|
| Sponsor/Collaborators: |
Novartis Pharmaceuticals|Novartis
|
| Gender: |
All
|
| Age: |
18 Years and older ?? (Adult, Older Adult)
|
| Phases: |
Phase 3
|
| Enrollment: |
10
|
| Study Type: |
Interventional
|
| Study Designs: |
Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment
|
| Start Date: |
February 19, 2020
|
| Completion Date: |
July 23, 2021
|
| Results First Posted: |
--
|
| Last Update Posted: |
January 13, 2022
|
| Locations: |
Novartis Investigative Site, Erlangen, Germany|Novartis Investigative Site, Frankfurt, Germany|Novartis Investigative Site, Muenchen, Germany|Novartis Investigative Site, Potsdam, Germany|Novartis Investigative Site, Stuttgart, Germany|Novartis Investigative Site, T??bingen, Germany|Novartis Investigative Site, Wuerzburg, Germany|Novartis Investigative Site, Valencia, Comunidad Valenciana, Spain
|
| URL: |
https://ClinicalTrials.gov/show/NCT04237116
|
